UY38261A - Agonistas del receptor de glp-1 y usos de los mismos - Google Patents

Agonistas del receptor de glp-1 y usos de los mismos

Info

Publication number
UY38261A
UY38261A UY0001038261A UY38261A UY38261A UY 38261 A UY38261 A UY 38261A UY 0001038261 A UY0001038261 A UY 0001038261A UY 38261 A UY38261 A UY 38261A UY 38261 A UY38261 A UY 38261A
Authority
UY
Uruguay
Prior art keywords
glp
receptor agonists
aza
benzimidazoles
compounds
Prior art date
Application number
UY0001038261A
Other languages
English (en)
Inventor
Kentaro Futatsugi
Kim Huard
Gary Erik Aspnes
Scott W Bagley
John M Curto
Mark E Flanagan
Chris Limberakis
Roger B Ruggeri
David James Edmonds
David A Griffith
Yajing Lian
Allyn T Londregan
Alan M ; Mathiowetz
David W ; Piotrowski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY38261A publication Critical patent/UY38261A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan en la presente ácidos 6-carboxílicos de bencimidazoles y 4-aza , 5-aza y 7 aza bencimidazoles como agonistas de GLP-1R, procesos para elaborar tales compuestos y métodos que comprenden administrar tales compuestos a un mamífero en necesidad de los mismos.
UY0001038261A 2018-06-13 2019-06-12 Agonistas del receptor de glp-1 y usos de los mismos UY38261A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684696P 2018-06-13 2018-06-13
US201962846944P 2019-05-13 2019-05-13
US201962851206P 2019-05-22 2019-05-22

Publications (1)

Publication Number Publication Date
UY38261A true UY38261A (es) 2020-01-31

Family

ID=67003576

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038261A UY38261A (es) 2018-06-13 2019-06-12 Agonistas del receptor de glp-1 y usos de los mismos

Country Status (38)

Country Link
US (5) US10934279B2 (es)
EP (2) EP4219487A1 (es)
JP (1) JP6916968B1 (es)
KR (1) KR102542199B1 (es)
CN (1) CN112533674A (es)
AU (1) AU2019285491B2 (es)
BR (1) BR112020024470A2 (es)
CA (1) CA3045644C (es)
CL (1) CL2020003222A1 (es)
CO (1) CO2020015305A2 (es)
CR (1) CR20200612A (es)
CU (1) CU20200099A7 (es)
CY (1) CY1126097T1 (es)
DK (1) DK3806955T3 (es)
EC (1) ECSP20078651A (es)
ES (1) ES2949954T3 (es)
FI (1) FI3806955T3 (es)
GE (1) GEP20237453B (es)
HR (1) HRP20230631T1 (es)
HU (1) HUE063074T2 (es)
IL (1) IL279300B2 (es)
LT (1) LT3806955T (es)
MD (1) MD3806955T3 (es)
MX (1) MX2020013625A (es)
NI (1) NI202000091A (es)
NZ (1) NZ770240A (es)
PE (2) PE20240584A1 (es)
PH (1) PH12020552069A1 (es)
PL (1) PL3806955T3 (es)
PT (1) PT3806955T (es)
RS (1) RS64323B9 (es)
SG (1) SG11202011465QA (es)
SI (1) SI3806955T1 (es)
TW (1) TWI707683B (es)
UA (1) UA124371C2 (es)
UY (1) UY38261A (es)
WO (1) WO2019239319A1 (es)
ZA (1) ZA202007572B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
EP3806855B1 (en) 2018-06-15 2023-03-01 Pfizer Inc. Glp-1 receptor agonists and uses thereof
BR112021009877A2 (pt) 2018-11-22 2021-08-17 Qilu Regor Therapeutics Inc. agonistas glp-1r e usos dos mesmos
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CA3140972C (en) * 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
KR20220092909A (ko) 2019-10-25 2022-07-04 길리애드 사이언시즈, 인코포레이티드 Glp-1r 조절 화합물
BR112022010599A2 (pt) * 2019-12-10 2022-08-16 Pfizer Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina
KR20220133271A (ko) * 2020-01-29 2022-10-04 길리애드 사이언시즈, 인코포레이티드 Glp-1r 조절 화합물
CR20220371A (es) 2020-02-07 2022-10-27 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
CN113493447B (zh) * 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
TW202144340A (zh) * 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2021249492A1 (zh) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
WO2021254470A1 (zh) * 2020-06-19 2021-12-23 江苏恒瑞医药股份有限公司 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN113816948B (zh) * 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
IL300155A (en) 2020-08-06 2023-03-01 Gasherbrum Bio Inc Heterocyclic GLP-1 agonists
TW202214622A (zh) * 2020-08-06 2022-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｇｌｐ－１ｒ促效劑及其用途
JP2023538949A (ja) 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CN115884969A (zh) * 2020-09-01 2023-03-31 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022068772A1 (zh) * 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
CN116547279A (zh) * 2020-10-13 2023-08-04 加舒布鲁姆生物公司 杂环glp-1激动剂
CN114478694A (zh) * 2020-11-13 2022-05-13 成都奥达生物科技有限公司 一种长效mc4r激动剂
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
MX2023006186A (es) 2020-11-27 2023-08-07 Shenzhen Salubris Pharm Co Ltd Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo.
CN114591308B (zh) * 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
US12065434B2 (en) 2020-12-15 2024-08-20 Pfizer Inc. Metabolites of GLP1R agonists
AU2022212019A1 (en) * 2021-01-28 2023-08-03 Carmot Therapeutics, Inc. Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
US11858918B2 (en) 2021-04-21 2024-01-02 Gilead Sciences, Inc. GLP-1R modulating compounds
CN117177970A (zh) * 2021-04-30 2023-12-05 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用
AU2022271223A1 (en) * 2021-05-03 2023-11-02 Carmot Therapeutics, Inc. Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CN117715906A (zh) * 2021-07-21 2024-03-15 和博医药有限公司 胰高血糖素样肽-1受体调节剂及其用途
CN113480534B (zh) * 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
MX2024001331A (es) * 2021-08-04 2024-04-19 Shanghai Hansoh Biomedical Co Ltd Regulador derivado del cicloalqueno, método de preparación de este y su aplicación.
AU2022333115A1 (en) * 2021-08-24 2024-04-04 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. Imidazocyclic compound and application thereof
AU2022344074A1 (en) 2021-09-08 2024-02-29 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
WO2023057427A1 (en) * 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057414A1 (en) * 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
CN115991685A (zh) 2021-10-20 2023-04-21 韶远科技（上海)有限公司 一种氧杂环丁烷-2-甲胺的制备方法
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
JPWO2023106310A1 (es) * 2021-12-07 2023-06-15
CN113974618B (zh) * 2021-12-12 2022-09-13 广西澍源智能科技有限公司 基于水峰血糖修正的无创血糖测试方法
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023116879A1 (zh) * 2021-12-23 2023-06-29 江苏恒瑞医药股份有限公司 一种glp-1受体激动剂的结晶形式及其制备方法
KR20240125003A (ko) * 2021-12-23 2024-08-19 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Glp-1 수용체 작용제의 약학적으로 허용 가능한 염, 결정 형태 및 이의 제조방법
CN116354945B (zh) * 2021-12-27 2024-08-30 长春金赛药业有限责任公司 一种稠合咪唑羧酸类化合物及其制备方法和应用
WO2023151574A1 (en) * 2022-02-09 2023-08-17 Gasherbrum Bio Inc. Heterocyclic glp-1 agonists
WO2023151575A1 (en) * 2022-02-09 2023-08-17 Gasherbrum Bio Inc. Heterocyclic glp-1 agonists
TW202342014A (zh) 2022-02-10 2023-11-01 瑞士商諾華公司 １，３－苯并二氧戊環衍生物
AU2023225875A1 (en) * 2022-02-28 2024-09-26 Ascletis Bioscience Co., Ltd. Glp-1r modulating compounds
WO2023169436A1 (zh) * 2022-03-08 2023-09-14 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
WO2023228023A1 (en) 2022-05-23 2023-11-30 Pfizer Inc. Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2024051749A1 (zh) * 2022-09-06 2024-03-14 德睿智药(苏州)新药研发有限公司 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途
WO2024063143A1 (ja) * 2022-09-22 2024-03-28 塩野義製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024160271A1 (zh) * 2023-02-02 2024-08-08 江苏豪森药业集团有限公司 一种环烯类化合物的盐、晶型及其制备方法和应用
USD1011080S1 (en) 2023-07-28 2024-01-16 Voilasophy, Llc. Yoga storage rack

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0689535B1 (en) 1993-03-18 1998-09-23 MERCK SHARP & DOHME LTD. Benzimidazole derivatives
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
JP2003512422A (ja) 1999-10-29 2003-04-02 メルク シャープ エンド ドーム リミテッド ベンズイミダゾールｎｍｄａ／ｎｒ２ｂアンタゴニストを使用する疼痛の治療方法
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
US7160879B2 (en) * 2002-01-10 2007-01-09 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues
US20040127504A1 (en) 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
MA33219B1 (fr) * 2009-03-30 2012-04-02 Transtech Pharma Inc Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
CH702192A1 (de) 2009-11-04 2011-05-13 New Dent Ag Keramisches Implantat.
WO2011097491A1 (en) 2010-02-04 2011-08-11 Glaxosmithkline Llc Benzimidazole antiviral agents
SG185515A1 (en) 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
US8859577B2 (en) 2010-09-30 2014-10-14 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
JP2016513112A (ja) 2013-02-18 2016-05-12 ザ スクリプス リサーチ インスティテュート 治療的潜在能力を有するバソプレッシン受容体のモジュレーター
WO2016029146A1 (en) 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
HUE054380T2 (hu) 2015-12-29 2021-09-28 Pfizer Helyettesített 3-azabiciklo[3.1.0]hexánok mint ketohexokináz inhibitorok
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CN106271089B (zh) 2016-09-30 2019-01-25 英诺激光科技股份有限公司 一种激光薄膜刻蚀装置及方法
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
CA3140972C (en) * 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases

Also Published As

Publication number Publication date
IL279300B2 (en) 2023-11-01
AU2019285491B2 (en) 2021-11-11
PH12020552069A1 (en) 2021-05-31
LT3806955T (lt) 2023-07-10
MX2020013625A (es) 2022-01-04
US20190382387A1 (en) 2019-12-19
CR20200612A (es) 2021-01-20
ZA202007572B (en) 2023-10-25
US20190382388A1 (en) 2019-12-19
EP3806955A1 (en) 2021-04-21
NI202000091A (es) 2021-03-23
ES2949954T9 (es) 2023-11-23
US10683281B2 (en) 2020-06-16
US10934279B2 (en) 2021-03-02
CU20200099A7 (es) 2021-08-06
NZ770240A (en) 2023-07-28
UA124371C2 (uk) 2021-09-01
TW202015679A (zh) 2020-05-01
KR20210019529A (ko) 2021-02-22
RU2769715C1 (ru) 2022-04-05
CA3045644A1 (en) 2019-12-13
CN112533674A (zh) 2021-03-19
CA3045644C (en) 2024-01-16
FI3806955T3 (fi) 2023-07-27
CL2020003222A1 (es) 2021-04-30
MD3806955T2 (ro) 2023-09-30
EP3806955B9 (en) 2023-08-23
RS64323B9 (en) 2023-11-30
TWI707683B (zh) 2020-10-21
IL279300A (en) 2021-01-31
HUE063074T2 (hu) 2023-12-28
AU2019285491A1 (en) 2020-12-17
US10676465B2 (en) 2020-06-09
RS64323B1 (sr) 2023-08-31
IL279300B1 (en) 2023-07-01
ES2949954T3 (es) 2023-10-04
PE20211601A1 (es) 2021-08-18
ECSP20078651A (es) 2021-01-29
PL3806955T3 (pl) 2023-09-04
US20210163455A1 (en) 2021-06-03
US20190382384A1 (en) 2019-12-19
SI3806955T1 (sl) 2023-08-31
DK3806955T3 (da) 2023-06-26
CO2020015305A2 (es) 2021-03-08
EP4219487A1 (en) 2023-08-02
HRP20230631T1 (hr) 2023-09-29
PT3806955T (pt) 2023-07-20
BR112020024470A2 (pt) 2021-03-02
PE20240584A1 (es) 2024-03-21
MD3806955T3 (ro) 2024-01-31
CY1126097T1 (el) 2023-11-15
US20240059679A1 (en) 2024-02-22
SG11202011465QA (en) 2020-12-30
WO2019239319A1 (en) 2019-12-19
EP3806955B1 (en) 2023-05-31
KR102542199B1 (ko) 2023-06-13
JP2021521265A (ja) 2021-08-26
JP6916968B1 (ja) 2021-08-11
GEP20237453B (en) 2023-01-10

Similar Documents

Publication Publication Date Title
ECSP20078651A (es) Agonistas del receptor de glp-1 y usos de los mismos
DOP2019000166A (es) Agonistas receptores de glp-1 y usos de los mismos
ZA202007304B (en) Glp-1 receptor agonists and uses thereof
ECSP18041501A (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
SV2018005799A (es) Compuestos moduladores de fxr (nr1h4)
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
AR092475A1 (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r
AR106908A1 (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
AR105592A1 (es) b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
CL2015002462A1 (es) Polímero conjugado para entregar un agente bioactivo
NI201500063A (es) Tratamiento de cáncer con pomalidomida en un individuo con daño renal
UY36455A (es) Antagonistas del receptor ep3 de prostaglandinas
CO2020006443A2 (es) Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CL2016002469A1 (es) Sulfamidasa modificada y su producción
CL2020001846A1 (es) Anticuerpos pac1 y sus usos
EA202092674A1 (ru) Агонисты рецептора glp-1 и их применение
UY35662A (es) Derivados de espiroindolina y composiciones farmacéuticas de los mismos
AR113814A1 (es) Métodos y composiciones para dosificar linfocitos t con receptor del antígeno quimérico alógenos